Gottlieb, A., A. Blauvelt, D. Tha?i, Y. Poulin, F. Brock, C. Arendt, M. Boehnlein, and K. Reich. “Reductions in Absolute PASI Over 144 Weeks of Treatment With Certolizumab Pegol in Patients With Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 6, Oct. 2020, p. s84, doi:10.25251/skin.4.supp.84.